A process suitable for kilogram-scale
synthesis of (2R)-2-methyl-6-nitro-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-dihydroimidazo[2,1-b][1,3]oxazole (DNDI-VL-2098, 2), a preclinical
drug candidate for the treatment of visceral leishmaniasis, is described.
The four-step synthesis of the target compound involves the Sharpless
asymmetric epoxidation of 2-methyl-2-propen-1-ol, 8.
Identification of a suitable synthetic route using retrosynthetic
analysis and development of a scalable process to access several kilograms
of 2 are illustrated. The process was simplified by employing
in situ synthesis of some intermediates, reducing safety hazards,
and eliminating the need for column chromatography. The improved reactions
were carried out on the kilogram scale to produce 2 in
good yield, high optical purity, and high quality.